Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SIOG 2017 /
Concluding the debate around dexrazoxane

9th - 11th Nov 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.11.17
Views: 1248

Dr Etienne Brain - Institut Curie, Paris, France

Dr Etienne Brain talks to ecancer at SIOG 2017 in Warsaw.

He discusses dexrazoxane and it's use to counteract the effects of anthrocyclines, and the difficulties in detecting the cardiovascular toxicity they cause.

The debate is whether dexrazoxane affect the efficacy of the chemotherapy.

He also discusses the age range it could be used for. 

This service has been kindly supported by an unrestricted grant from Janssen Oncology.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation